Data Insights

Penpulimab by Akeso for Glioblastoma Multiforme (GBM): Likelihood of Approval

Penpulimab is under clinical development by Akeso and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...

Data Insights

Penpulimab by Akeso for Non-Small Cell Lung Cancer: Likelihood of Approval

Penpulimab is under clinical development by Akeso and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Penpulimab in Non-Small Cell Lung Cancer

Data Insights

Penpulimab by Akeso for Cervical Cancer: Likelihood of Approval

Penpulimab is under clinical development by Akeso and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Penpulimab in Cervical Cancer

Data Insights

Penpulimab by Akeso for Nasopharyngeal Cancer: Likelihood of Approval

Penpulimab is under clinical development by Akeso and currently in Pre-Registration for Nasopharyngeal Cancer. According to GlobalData, Pre-Registration drugs for...

Likelihood of Approval and Phase Transition Success Rate Model - Penpulimab in Nasopharyngeal Cancer

Data Insights

Penpulimab by Akeso for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Penpulimab is under clinical development by Akeso and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Penpulimab in Metastatic Adenocarcinoma of The Pancreas

Data Insights

Penpulimab by Akeso for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Penpulimab is under clinical development by Akeso and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Penpulimab in Triple-Negative Breast Cancer (TNBC)